Daily tailored amino acid supplement for people with Parkinson's disease
Official title: Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers
Run by University of Connecticut · NCT07115563 · Data updated 2026-11-12
This test will see if taking a daily tailored amino acid supplement for six months helps adults with Parkinson's disease improve nutrition, metabolism, body composition, and physical and mental function.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 90 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | University of Connecticut Academic / other |
| Locations | 2 sites (Farmington, Connecticut and 1 other locations) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | September 2027 |
| Study ends | November 2027 |
| Registry record updated | August 13, 2026 |
| Trial ID | NCT07115563 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 60–80 with idiopathic Parkinson's disease who have used dopamine-replacement medication for at least two years and have been on a stable dose for at least three months.
✕Probably not a fit
People with atypical Parkinsonism, significant cognitive impairment, unstable medical conditions, use of dopamine antagonists or blood thinners, prior gastric/bowel resection, deep brain stimulation, or contraindications to blood draw may not be eligible or likely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults aged 60–80 with idiopathic Parkinson's disease on stable dopamine-replacement therapy take either a targeted amino acid supplement or a placebo daily for six months. Researchers measure plasma amino acid availability, an antioxidant-related complex amino acid and an amino acid linked to oxidative stress, metabolic markers, body composition, physical function, and self-reported outcomes. Participants attend lab visits at baseline and three months for blood draws and functional testing, with monitoring for adherence and safety. The placebo-controlled comparison is designed to determine whether correcting PD-associated amino acid deficiencies leads to measurable clinical and biochemical improvements.
Why it matters
Potential benefit: If successful, the supplement could improve nutritional status, lower oxidative-stress–related amino acids, and lead to better physical and mental functioning for people with Parkinson's disease.
How similar studies have gone: Nutritional and amino acid approaches have shown mixed but sometimes encouraging results in small studies, while a specifically tailored amino acid supplement for PD is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusionary Criteria: * Male and Females. * 50-80 Years. * Previous diagnosis of idiopathic Parkinson's Disease by patient report. * Use of dopamine replacement medication (e.g. levodopa) for at least 2 years. * On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months. Exclusionary criteria * Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status \<29). * Diagnosis of Parkinsonism or atypical Parkinson's Disease. * Prescription of Dopamine antagonist. * Any unstable medical condition. * Use of Deep Brain Stimulation. * Gastric or Bowel resection surgery. * Contraindications to blood draw.
Where it's running
-
UConn Health
Farmington, Connecticut, United States Recruiting -
University of Connecticut
Storrs, Connecticut, United States Recruiting
Study contacts
- Study coordinator: Carlos Rehbein, MS
- Email: carlos.rehbein@uconn.edu
- Phone: 860-634-8203
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Parkinson’s Risk in Gaucher Disease Type 1
This study tests how Parkinson’s risk relates to GBA1-related Gaucher disease in adults over 40, by collecting detailed clinical data and samples for future research.
-
Can the Ronnie Gardiner Method improve thinking and daily function in people with Parkinson’s
In this 10-week program, adults with Parkinson’s disease will try the Ronnie Gardiner Method to see if it helps thinking, talking, movement, balance, and quality of life.
-
Effects of excitatory and inhibitory LIFUS of GPi in Parkinson’s patients without DBS
This study tests two deep-brain focused ultrasound patterns on people with Parkinson’s to see if they change task performance and tremor, compared with a sham stimulation.
-
Capacitive-resistive radiofrequency therapy for people with Parkinson's disease
This study tests four TECAR therapy protocols on the legs to see which best reduces muscle stiffness and improves walking in people with Parkinson's disease.
-
TRB-001 safety and immune response in early Parkinson's disease
This early-phase study tests TRB-001 against placebo to see if it is safe and prompts an immune response in people with recently diagnosed Parkinson’s disease.
-
Bayesian optimization to tune DBS for better gait in Parkinson’s patients
This study tests whether using Bayesian optimization can quickly find DBS settings that lengthen step length in people with Parkinson's who already have DBS in place.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.